A method of antitumor therapy is described in which administration of a chemotherapeutic drug, encapsulated in liposomes, is supplemented by administration of an immunostimulating cytokine. The cytokine is preferably also encapsulated in liposomes. In tumor models for lung and colon carcinomas, this method produced a significantly greater therapeutic effect, as evidenced by survival rate and tumor size, than a combination of the effects produced by the free or liposome–encapsulated components administered individually.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>AL</td>
<td>Albania</td>
<td>ES</td>
<td>Spain</td>
<td>LS</td>
<td>Lichtenstein</td>
<td>SK</td>
<td>Slovenia</td>
</tr>
<tr>
<td>AM</td>
<td>Armenia</td>
<td>FI</td>
<td>Finland</td>
<td>LT</td>
<td>Lithuania</td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td>AT</td>
<td>Austria</td>
<td>FR</td>
<td>France</td>
<td>LU</td>
<td>Luxembourg</td>
<td>SZ</td>
<td>Swaziland</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GA</td>
<td>Gabon</td>
<td>LV</td>
<td>Latvia</td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td>AZ</td>
<td>Azerbaijan</td>
<td>GB</td>
<td>United Kingdom</td>
<td>MC</td>
<td>Monaco</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>BA</td>
<td>Bosnia and Herzegovina</td>
<td>GE</td>
<td>Georgia</td>
<td>MD</td>
<td>Republic of Moldova</td>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GH</td>
<td>Ghana</td>
<td>MG</td>
<td>Madagascar</td>
<td>TM</td>
<td>Turkmenistan</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GN</td>
<td>Guinea</td>
<td>MK</td>
<td>The former Yugoslav</td>
<td>TR</td>
<td>Turkey</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GR</td>
<td>Greece</td>
<td>ML</td>
<td>Mali</td>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>HU</td>
<td>Hungary</td>
<td>MN</td>
<td>Mongolia</td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IE</td>
<td>Ireland</td>
<td>MR</td>
<td>Mauritania</td>
<td>UG</td>
<td>Uganda</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>IL</td>
<td>Israel</td>
<td>MW</td>
<td>Malawi</td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>IS</td>
<td>Iceland</td>
<td>MX</td>
<td>Mexico</td>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
<td>NE</td>
<td>Niger</td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
<td>NL</td>
<td>Netherlands</td>
<td>YU</td>
<td>Yugoslavia</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KE</td>
<td>Kenya</td>
<td>NO</td>
<td>Norway</td>
<td>ZW</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KG</td>
<td>Kyrgyzstan</td>
<td>NZ</td>
<td>New Zealand</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
<td>PL</td>
<td>Poland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>KR</td>
<td>Republic of Korea</td>
<td>PT</td>
<td>Portugal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>KZ</td>
<td>Kazakhstan</td>
<td>RO</td>
<td>Romania</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CU</td>
<td>Cuba</td>
<td>LC</td>
<td>Saint Lucia</td>
<td>RU</td>
<td>Russian Federation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>LI</td>
<td>Liechtenstein</td>
<td>SD</td>
<td>Sudan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>LK</td>
<td>Sri Lanka</td>
<td>SE</td>
<td>Sweden</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>LR</td>
<td>Liberia</td>
<td>SG</td>
<td>Singapore</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EE</td>
<td>Estonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SI</td>
<td>Slovenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SK</td>
<td>Slovakia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SZ</td>
<td>Swaziland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TG</td>
<td>Togo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES

Field of the Invention

The present invention relates to a method and composition for antitumor therapy, and more particularly to combination therapy using a chemotherapeutic drug and an immunostimulating cytokine. Sequential administration of these two components, both encapsulated in liposomes, is shown to have a significant antitumor effect as compared to administration of the individual components, in free form or in liposomes.

References


Background of the Invention

Despite prolific research in the area of cancer chemotherapy, such treatment remains far from satisfactory. The inability of chemotherapeutic drugs to reach the tumor site, intrinsic and acquired cross-resistance to multiple chemotherapeutic agents, and, especially, the high toxicity of many of these agents all contribute to treatment failures.

The use of immunostimulating cytokines, such as IL-2 and interferon-α, has proven to be effective in treatment of a proportion of patients with malignancies such as melanoma and renal cell carcinoma, both alone and in combination with other therapeutic agents. However, major problems limit their wide clinical use, including rapid plasma clearance, biodistribution to nonrelevant tissues, and high toxicity. Furthermore, their efficacy has been low in treatment of the most common tumors, e.g. colorectal, mammary, prostate, and lung carcinomas.
Summary of the Invention

The present invention includes, in one aspect, a method of antitumor therapy, which comprises administering to a subject in need of such treatment, a therapeutically effective amount of a combination of a chemotherapeutic drug and an immunostimulating cytokine, both encapsulated in liposomes. In another aspect, the invention provides a composition for use in antitumor therapy, which comprises such a combination of a chemotherapeutic drug and an immunostimulating cytokine, both encapsulated in liposomes. Administration of the combination produces a greater therapeutic effect than a combination of the effects produced by the liposome-encapsulated components administered individually.

The invention also includes a method of antitumor therapy in which a chemotherapeutic drug, encapsulated in liposomes, is administered in combination with a cytokine, which may or may not be encapsulated in liposomes. In this method, the drug is encapsulated in liposomes which contain about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 daltons. The therapeutic effect of this combination is greater than a combination of the effects produced by the liposome-encapsulated drug and the cytokine administered individually.

In all cases, administration of the cytokine preferably follows administration of the liposome-encapsulated drug.

The chemotherapeutic drug is preferably selected from cis-platin, a chemotherapeutic anthraquinone, and a topoisomerase I inhibitor, such as camptothecin or a camptothecin analog. More preferably, the drug is adriamycin (doxorubicin), in which case the liposome-encapsulated form of the drug is preferably DOXIL®.

The immunostimulating cytokine is preferably selected from the group consisting of interleukin-2 (IL-2), IL-12, IL-15, IL-18, IFN-γ, IFN-α, IFN-β, TNF-α, G-CSF, and GM-CSF. More preferably, the cytokine is IL-2.

The encapsulating liposomes employed in the composition and method preferably contain at least one lipid selected from dimyristoyl phosphatidyl choline (DMPC), dimyristoyl phosphatidyl glycerol (DMPG), 1,2-distearoyl-3-trimethylammonium propane (DSTAP), phosphatidyl choline, phosphatidyl ethanolamine, and cholesterol.

The liposomes may be small unilamellar vesicles (SUV), defined as having a mean diameter of approximately 20 to 100 nm, or large unilamellar vesicles (LUV), defined as having a mean diameter of approximately 100 to 200 nm. Such liposomes preferably contain about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 daltons.

Alternatively, the liposomes may be large multilamellar vesicles (MLV) having a mean
diameter of approximately 250 to 2000 nm. The MLV may also contain a PEG-derivatized lipid as described above.

In preferred embodiments, the chemotherapeutic drug is encapsulated in vesicles having a mean diameter of approximately 50 to 120 nm, and containing about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain as described above. In another preferred embodiment, the cytokine is encapsulated in liposomes containing dimyristoyl phosphatidyl choline (DMPC) plus 0 to 50 mole percent of at least one lipid selected from dimyristoyl phosphatidyl glycerol (DMPG) and 1,2-distearoyl-3-trimethylammonium propane (DSTAP).

These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.

**Brief Description of the Drawings**

Figure 1 shows the survival rate of BALB/c mice injected intraperitoneally with $5 \times 10^5$ M109 tumor cells (lung adenocarcinoma) and subsequently treated with free adriamycin or DOXIL®, respectively, alone or in combination with intraperitoneal IL-2 in DMPC/DMPG MLV liposomes, or with liposomal IL-2 alone; and

Figure 2 shows the survival rate of BALB/c mice injected intravenously with $5 \times 10^5$ M109 tumor cells and subsequently treated with DOXIL® (at day 7), alone or in combination with intravenous IL-2 in Stealth® PEGylated SUV liposomes (at days 11, 14, and 17), or with liposomal IL-2 alone (at days 11, 14, and 17).

**Detailed Description of the Invention**

I. **Definitions**

The terms below have the following meanings unless indicated otherwise.

"Vesicle-forming lipids" refers to amphipathic lipids which have hydrophobic and polar head group moieties, and which (a) can form bilayer vesicles in water, as exemplified by phospholipids, or (b) can be stably incorporated into lipid bilayers, with the hydrophobic moiety in contact with the interior, hydrophobic region of the bilayer membrane, and the polar head group moiety oriented toward the exterior, polar surface of the membrane.

The vesicle-forming lipids of this type typically include one or two hydrophobic acyl hydrocarbon chains or a steroid group, and may contain a chemically reactive group, such as an amine, acid, ester, aldehyde or alcohol, at the polar head group. Included in this class are the phospholipids, where the two hydrocarbon chains are typically between about 14-22 carbon atoms
in length, and have varying degrees of unsaturation. Representative examples are phosphatidylcholine (PC), phosphatidyl ethanolamine (PE), phosphatidic acid (PA), phosphatidyl inositol (PI), sphingomyelin (SM), negatively charged lipids such as dimyristoyl phosphatidyl glycerol (DMPG), and positively charged lipids such as 1,2-distearoyl-3-trimethylammonium propane (DSTAP). The liposomes may also contain sterols, such as cholesterol, which do not form liposomes themselves but can be incorporated into, and may stabilize, liposomes containing lipids such as those described above.

A "Cetus unit" (CU) is equal to six International Units (IU) of Immunological Activity, the international reference standard of a biological preparation of interleukin-2 (IL-2). The term "unit" used herein in reference to cytokine levels refers to Cetus units.

II. Liposomal Compositions

A. Lipid Components

Various vesicle-forming lipids, as defined above, may be used in the present liposomal compositions, according to methods well known in the art. Preferred lipids for the current invention allow long-term storage of the liposome-entrapped agents and effective release of these components upon administration. Representative lipids include, but are not limited to, dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), cholesterol, egg phosphatidylcholine (egg PC), phosphatidyl ethanolamine (PE), distearoyl phosphatidyl ethanolamine (DSPE), phosphatidyl inositol (PI), 1,2-distearoyl-3-trimethylammonium propane (DSTAP), 1,2-dimyristoyl-3-trimethylammonium propane (DMTAP), and combinations thereof.

The vesicle-forming lipids, preferably those making up SUV's, may contain about 1-10 mole percent of a lipid having a polar head group, typically a phosphate containing head group, derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 daltons. The rate of clearance of liposomes from circulation is typically reduced by employing such PEG-derivatized, or "PEGylated", lipids. PEG coating is believed to inhibit nonspecific adsorption of serum proteins, thereby preventing nonspecific recognition of liposomes by macrophages (Papahadjopoulos, et al., 1991). Another advantage of these long-circulating liposomes is their good extravasation capacity and high accumulation in tumors (Lasic and Martin, 1995; Gabizon, et al., 1997). They are also referred to as sterically stabilized liposomes, SSL, or Stealth® liposomes.

The preparation of such lipids is described in, for example, Woodle, et al., 1991; Sears (1984, 1985); Tirosh et al. (1997) or copending and co-owned application having U.S. serial number 08/570,440. The PEG chain may be linked directly to the phosphatidic acid head group of a phospholipid. Various other linkages are possible; for example, lipids containing a phosphatidyl
ethanolamine (PE) or other amino head group may be conveniently coupled to activated PEG chains via reaction with brominated PEG. PEG-modified lipids are also commercially available, *e.g.* from Sequus Corporation, Menlo Park, CA.

**B. Preparation of Liposomes and Liposomal Compositions**

Liposomes may be prepared by a variety of techniques, such as those detailed in Szoka *et al.* (1980b). To form multilamellar vesicles (MLV’s), a mixture of vesicle-forming lipids dissolved in a suitable solvent is evaporated in a vessel to form a thin film, which is then hydrated by an aqueous medium to form MLV’s, typically with sizes between about 0.1 to 10 microns. Tert-butanol is a preferred solvent for the process. The MLV’s may then be downsized to a desired size range by extruding the aqueous suspension through a polycarbonate membrane having a selected uniform pore size, typically 0.05 to 1.0 microns.

Preparations of MLV’s or REV’s (described below) may be treated, *e.g.* by extrusion, sonication or high pressure homogenization, to produce unilamellar vesicles. Small unilamellar vesicles (SUV’s) are characterized by sizes in the 30-100 nm range, while large unilamellar vesicles (LUV’s) are defined as those having mean diameters of about 100-200 nm. SUV’s may also be formed directly by high pressure homogenization of an aqueous dispersion of lipids.

Various methods are available for encapsulating other agents in liposomes. Preparation of SSL-encapsulated IL-2 is described in Kedar *et al.* (1994). In this procedure, generally, the lipid components, including a PEG-substituted lipid, are dissolved in t-butanol. The solution is sonicated, and IL-2 is added with further sonication. The mixture is lyophilized and rehydrated, forming MLV’s, which can then be downsized by high pressure homogenization or by successive extrusion through polycarbonate filters. These downsizing methods gave vesicles having diameters of 50-80nm and about 200nm, respectively. The procedure achieved approximately 80-90% encapsulation of the IL-2.

In the reverse phase evaporation method (Szoka, *et al.*, 1980a) a nonaqueous solution of vesicle-forming lipids is dispersed with a smaller volume of an aqueous medium to form a water-in-oil emulsion. The agent to be incorporated is included either in the lipid solution, in the case of a lipophilic agent, or in the aqueous medium, in the case of a water-soluble agent. After removal of the lipid solvent, the resulting gel is converted to liposomes. These reverse phase evaporation vesicles (REV’s) have typical average sizes between about 0.2-4 microns and are predominantly oligolamellar, that is, containing one or a few lipid bilayer shells. The REV’s may be sized by extrusion, if desired, to give oligolamellar vesicles having a maximum selected size between about 0.05 to 1.5 microns.

Other methods for adding additional components to liposomal compositions include colyophilization with other components and redispersion of the resulting solid to form MLV’s. In a
method described by Adler, et al. (1995), an aqueous solution of the agent to be encapsulated is added to a t-butanol solution of lipids. The mixture is sonicated and lyophilized, and the resulting powder is rehydrated.

Liposome compositions containing an entrapped agent may be treated after final sizing, if necessary, to remove free (non-entrapped) agent. Conventional separation techniques, such as centrifugation, diafiltration, and molecular-sieve chromatography are suitable for this purpose. The composition may also be sterilized by filtration through a conventional 0.22 or 0.45 micron depth filter.

To form the compositions of the current invention, the concentration of drug and/or cytokine in the liposomes is preferably effective to give a protein/lipid weight ratio between about 1:100 and 1:1000.

Stabilizers may also be added to the liposomal compositions. For example, addition of a metal chelator such as Desferal® or diethylenetriamine pentaacetic acid (DTPA) to the lyophilization medium, at a concentration of 100 μM, has been shown to reduce activity loss of entrapped IL-2 during liposome preparation and storage at 4°C. Antioxidants such as BHT or Vitamin E may also be included.

For long term storage, the compositions may be stored as the dry lyophilized powder, which is stable for at least a year at 4°C, and hydrated to form an aqueous suspension before use.

III. Combined Chemotherapy/Cytokine Therapy

A. Formulations

Cytokines useful for enhancing antitumor activity of chemotherapeutic drugs include IL-2, IL-12, IL-15, IL-18, IFN-γ, IFN-α, IFN-β, TNF-α, G-CSF, and GM-CSF. A preferred cytokine for the present invention is IL-2 (interleukin 2), which acts as a growth and maturation factor for T-lymphocytes.

A variety of liposomal formulations may be used for encapsulation of the cytokine. These include MLV, LUV or SUV, as defined above, as well as OLV (oligolamellar vesicles) and MVV (multivesicular vesicles), composed of vesicle-forming lipids such as those described above. Combinations of lipids are generally most effective (see, for example, Kedar et al., 1994). One preferred type of formulation employs SUV or LUV, having a mean diameter of approximately 50 to 120 nm, containing about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain (also referred to as a PEGylated lipid). Formulation A below is one example. Other preferred formulations employ dimyristoyl phosphatidyl choline (DMPC) and, optionally, up to 50 mole percent of at least one lipid selected from dimyristoyl phosphatidyl glycerol (DMPG) and 1,2-distearoyl-3-trimethylammonium propane (DSTAP). In
these formulations, the proportion of DMPG and/or DSTAP is more preferably 5 - 25 mole
percent. Formulation B below is one example. In all cases, small quantities (up to about one mole
percent) of stabilizers such as tocopherol or Desferal™ may be included.

For the experiments described below, liposomal IL-2 was prepared in two formulations, using
5 IL-2 obtained from Chiron Corporation (Emeryville, CA), according to known methods such as
those described above. Formulation A employed sterically stabilized (SSL) small unilamellar
vesicles (SUV) composed of 2000PEG-DSPE (N-carbamyl-(polyethylene glycol methyl ether)-1,2-
distearoyl-sn-glycero-3-phosphoethanolamine triethylammonium salt, provided by Sequus
Corporation), egg phosphatidyl choline, and cholesterol in a molar ratio of about 5:55:40. The
vesicles were about 50-70 nm in diameter. Encapsulation efficiency of IL-2 was greater than 80%,
based on an in vitro IL-2 bioassay (i.e., > 80% of the initial amount of added IL-2 became
encapsulated in liposomes).

Formulation B employed multilamellar vesicles (MLV) composed of DMPC-DMPG
(dimyristoyl phosphatidyl choline - dimyristoyl phosphatidyl glycerol) in a 9:1 molar ratio. The
vesicles were approximately 500-1500 nm in size, and the encapsulation efficiency was
approximately > 90%. This high efficiency of encapsulation was achieved at a lipid:IL-2 ratio
(wt:wt) of 1000:1 for DMPC alone, and 100:1 for DMPC containing DMPG or DSTAP.

The chemotherapeutic drug is preferably encapsulated in liposomes having about 1-10 mole
percent of a PEGylated lipid, as described above. For example, DOXIL®, a stable formulation of
20 adriamycin in Stealth® liposomes, is available from SEQUUS Pharmaceuticals, Inc. (Menlo Park,
CA). Free adriamycin is available, e.g., from Cetus Oncology Corp. (Emeryville, CA) as a
formulation of doxorubicin hydrochloride and lactose.

Other chemotherapeutic drugs which are also preferred for the present method include other
anthraquinones, such as epirubicin, daunorubicin, and mitoxantrone, and cis-platin. Also
25 contemplated are topoisomerase I inhibitors such as camptothecin and its analogs, e.g. topotecan
and irinotecan, also designated CPT-11. Camptothecin is isolated from the stem wood of the
Chinese tree Camptotheca acuminata; preparation of the above noted analogs has been described
by, e.g., Curran et al. (1996).

B. Liposomal Adriamycin - Liposomal IL-2

The effect of adriamycin, used alone or in combination with interleukin-2 (IL-2), where each
component was in free or liposome-encapsulated form, on the survival rate of BALB/c mice
infected with tumor cells, was tested as described below.

B1. Lung Adenocarcinoma Model: IL-2 in MLV. Six groups of BALB/c mice were injected
30 intraperitoneally with 5 x 10⁴ M109 tumor cells (day 0). Free adriamycin or DOXIL®,
respectively, were administered intravenously on day 7 at a dose of 8 mg/kg, and intraperitoneal
cytokine treatment was initiated 3 days later. Liposomal IL-2 (formulation B; MLV DMPC/DMPG (9:1 mole ratio) liposomes containing IL-2) was given once daily (50,000 CU/mouse) on days 10, 13 and 16. Control groups received no treatment or received the IL-2 treatment alone.

Each group, consisting of 8-9 mice, was inspected for survival up to 100 days after tumor inoculation. Table I shows the number of survivors at the end of the experiment and the median survival time obtained; Figure 1 shows the survival curves for all groups.

### Table I

<table>
<thead>
<tr>
<th>GROUP</th>
<th>TREATMENT</th>
<th>NUMBER OF SURVIVING MICE/TOTAL</th>
<th>MEDIAN SURVIVAL (DAYS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>2/8</td>
<td>54</td>
</tr>
<tr>
<td>2</td>
<td>ADR</td>
<td>0/8</td>
<td>42</td>
</tr>
<tr>
<td>3</td>
<td>ADR + MLV-IL-2</td>
<td>5/8</td>
<td>&gt;100</td>
</tr>
<tr>
<td>4</td>
<td>DOXIL®</td>
<td>5/8</td>
<td>&gt;100</td>
</tr>
<tr>
<td>5</td>
<td>DOXIL® + MLV-IL-2</td>
<td>8/8</td>
<td>&gt;100</td>
</tr>
<tr>
<td>6</td>
<td>MLV-IL-2</td>
<td>1/9</td>
<td>21</td>
</tr>
</tbody>
</table>

As Table I shows, Adriamycin (ADR) in combination with MLV-IL-2 (liposomal IL-2, formulation B) was much more effective than either Adriamycin alone or liposomal IL-2 alone, both of which showed lower survival rates than the control. When liposomal Adriamycin (DOXIL®) was administered alone, or when non-liposomal Adriamycin was combined with liposomal IL-2, five of eight mice survived for the duration of the test.

The best result, i.e. survival of all subjects for 100 days or more, was observed for the combination of liposomal ADR (DOXIL®) with liposomal IL-2. In terms of number of surviving subjects, the effect of the combination treatment was greater than a combination of the effects of the individual treatments.

B2. Metastatic Lung Adenocarcinoma Model: IL-2 in MLV (Formulation B) and PEG-Derivatized SUV (SSL). In this experiment, BALB/c mice were injected intravenously with $5 \times 10^5$ M109 tumor cells (day 0). Free Adriamycin or DOXIL®, respectively, were administered intravenously on day 7 (8 mg/kg), followed 3 days later by intravenous cytokine treatment.

Liposomal IL-2 (Formulation A; PEGylated SUV containing IL-2) was given once daily (50,000 CU/mouse) on days 11, 14 and 17. Control groups received no treatment or received the IL-2 treatment alone.

Each group, consisting of 8-9 mice, was inspected for survival up to 100 days after tumor inoculation.
inoculation. Results are shown in Table II and Figure 2.

### TABLE II

<table>
<thead>
<tr>
<th>GROUP</th>
<th>TREATMENT</th>
<th>NUMBER OF SURVIVING MICE/TOTAL</th>
<th>MEDIAN SURVIVAL (DAYS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>0/8</td>
<td>43</td>
</tr>
<tr>
<td>2</td>
<td>ADR</td>
<td>2/8</td>
<td>56</td>
</tr>
<tr>
<td>3</td>
<td>DOXIL®</td>
<td>1/8</td>
<td>66</td>
</tr>
<tr>
<td>4</td>
<td>SSL-IL-2</td>
<td>0/8</td>
<td>41</td>
</tr>
<tr>
<td>5</td>
<td>DOXIL® + SSL-IL-2</td>
<td>7/9</td>
<td>&gt;100</td>
</tr>
</tbody>
</table>

As a comparison of groups 3-5 shows, the combined treatment with DOXIL® and liposomal IL-2 was significantly more effective than treatment with either liposomal component alone, particularly in terms of the number of subjects surviving for the duration of the test, i.e. 100 days or more (7 out of 9 compared to 0-1 out of 8). In this aspect, the combined treatment was significantly more effective than a combination of the effects derived from the individual therapies.

In a second, more extensive study, nine groups of BALB/c mice were injected intraperitoneally with $5 \times 10^5$ M109 tumor cells. Free adriamycin or DOXIL® (8 mg/kg) were administered intraperitoneally 7 days later, followed 3 days later by intravenous cytokine treatment. The cytokine, given once daily (50,000 CU/mouse) on days 10, 13 and 16, consisted of free IL-2, IL-2 in Formulation A (Stealth® PEGylated SUV), or IL-2 in Formulation B (9:1 molar DMPC/DMPG MLV).

Each group, consisting of 8 mice, and an untreated control group of 11 mice, were inspected for survival up to 120 days after tumor inoculation. Results are shown in Table III.
### TABLE III

<table>
<thead>
<tr>
<th>GROUP</th>
<th>TREATMENT</th>
<th>NUMBER OF TUMOR FREE MICE/TOTAL</th>
<th>MEDIAN SURVIVAL (DAYS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>3/11</td>
<td>69</td>
</tr>
<tr>
<td>2</td>
<td>ADR</td>
<td>4/8</td>
<td>100</td>
</tr>
<tr>
<td>3</td>
<td>ADR/free IL-2</td>
<td>3/8</td>
<td>53</td>
</tr>
<tr>
<td>4</td>
<td>ADR/MLV-IL-2</td>
<td>4/8</td>
<td>92</td>
</tr>
<tr>
<td>5</td>
<td>ADR/SSL-IL-2</td>
<td>3/8</td>
<td>72</td>
</tr>
<tr>
<td>6</td>
<td>DOXIL®</td>
<td>4/8</td>
<td>102</td>
</tr>
<tr>
<td>7</td>
<td>DOXIL®/free IL-2</td>
<td>5/8</td>
<td>&gt;120</td>
</tr>
<tr>
<td>8</td>
<td>DOXIL®/MLV-IL-2</td>
<td>7/8</td>
<td>&gt;120</td>
</tr>
<tr>
<td>9</td>
<td>DOXIL®/SSL-IL-2</td>
<td>5/8</td>
<td>&gt;120</td>
</tr>
</tbody>
</table>

In this study, administration of free ADR and IL-2 showed little or no benefit over free ADR alone (groups 2-5). However, combinations of either free or liposomal IL-2 with the chemotherapeutic drug in liposomes (DOXIL®) showed clear benefits over administration of the drug alone (groups 6-9). Overall, the groups (8 and 9) treated with a combination of both components in liposomes showed superior results. Group 8, in particular, showed a high survival rate and almost a complete absence of tumors.

### TABLE IV

<table>
<thead>
<tr>
<th>GROUP</th>
<th>TREATMENT</th>
<th>NUMBER OF TUMOR FREE MICE, DAY 30</th>
<th>NUMBER OF TUMOR FREE MICE, DAY 65</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Control</td>
<td>0/7</td>
<td>0/7</td>
</tr>
<tr>
<td>2</td>
<td>ADR</td>
<td>0/7</td>
<td>0/7</td>
</tr>
<tr>
<td>3</td>
<td>ADR/free IL-2</td>
<td>0/7</td>
<td>0/7</td>
</tr>
<tr>
<td>4</td>
<td>ADR/MLV-IL-2</td>
<td>1/8</td>
<td>0/8</td>
</tr>
<tr>
<td>5</td>
<td>DOXIL®</td>
<td>4/8</td>
<td>102</td>
</tr>
<tr>
<td>6</td>
<td>DOXIL®/free IL-2</td>
<td>3/8</td>
<td>2/8</td>
</tr>
<tr>
<td>7</td>
<td>DOXIL®/MLV-IL-2</td>
<td>6/8</td>
<td>4/8</td>
</tr>
</tbody>
</table>

B3. Subcutaneous colon carcinoma model: IL-2 in MLV. In this test, 7 groups of BALB/c mice were injected in the footpad with 10^5 C26 colon carcinoma cells. Seven days later, 8 mg/kg free or liposomal adriamycin was administered i.v. Free or liposomal IL-2, as shown in Table IV, was administered i.p. according to the schedule described above. Results are shown in Table IV.
As the data shows, administration of liposomal drug alone was somewhat beneficial, but only the group receiving the combined liposomal treatment showed significant recovery from tumors. In this group (group 7), it was also observed that the tumors were significantly smaller than in the other groups.

IV. Administration

For use in humans, a therapeutically effective dose of the composition typically corresponds to 20-100 mg adriamycin/m² of body surface. For IL-2, a preferred dose corresponds to 50,000 - 500,000 CU per square meter of body surface. Administration may be by intraperitoneal (ip), subcutaneous (sc), intravenous (iv), intraarterial (ia), or intramuscular (im) injection. Liposomes in the form of large multilamellar vesicles (MLV's) are preferred for intraperitoneal, subcutaneous or intramuscular administration, while SUV's are preferred for intravenous as well as intramuscular administration.

As shown above, administration of liposome-encapsulated chemotherapeutic drug is followed by administration of the liposome-encapsulated cytokine. While specific time intervals and courses of treatment have been shown in the examples above, it is understood that dosages, time intervals between courses, and the number of courses of treatment, for both drug and cytokine, may be varied depending on the extent of symptoms and the condition of the patient.

While the invention has been described with reference to specific methods and embodiments, it will be appreciated that various modifications may be made without departing from the invention.
IT IS CLAIMED:

1. A method of antitumor therapy, comprising administering to a subject in need of such treatment, a therapeutically effect amount of a combination of components encapsulated in liposomes, wherein said components comprise a chemotherapeutic drug and an immunostimulating cytokine.

2. The method of claim 1, wherein said administering produces a greater therapeutic effect than a combination of the effects produced by the liposome-encapsulated components administered individually.

3. The method of claim 1, wherein the liposomes contain about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 daltons.

4. The method of claim 1, wherein the liposomes contain at least one lipid selected from the group consisting of dymristoyl phosphatidyl choline, dymristoyl phosphatidyl glycerol, 1,2-distearoyl-3-trimethylammonium propane, phosphatidyl choline, phosphatidyl ethanolamine, and cholesterol.

5. The method of claim 1, wherein the chemotherapeutic drug is encapsulated in vesicles having a mean diameter of approximately 50 to 120 nm, and containing about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 daltons.

6. The method of claim 1, wherein the chemotherapeutic drug is selected from a chemotherapeutic anthraquinone, cis-platin, and a topoisomerase I inhibitor.

7. The method of claim 6, wherein the chemotherapeutic anthraquinone is adriamycin.

8. The method of claim 6, wherein the topoisomerase I inhibitor is camptothecein or a camptothecein analog.

9. The method of claim 7, wherein the chemotherapeutic drug encapsulated in liposomes is DOXIL®.

10. The method of claim 1, wherein the cytokine is selected from the group consisting of
interleukin-2 (IL-2), IL-12, IL-15, IL-18, IFN-γ, IFN-α, IFN-β, TNF-α, G-CSF, and GM-CSF.

11. The method of claim 10, wherein the cytokine is IL-2.

12. The method of claim 1, wherein the cytokine is encapsulated in liposomes comprising dimyristoyl phosphatidyl choline plus 0 - 50 mole percent of at least one lipid selected from dimyristoyl phosphatidyl glycerol and 1,2-distearoyl-3-trimethylammonium propane.

13. The method of claim 1, wherein administration of the liposome-encapsulated cytokine follows administration of the liposome-encapsulated chemotherapeutic drug.

14. A method of antitumor therapy, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a combination of a chemotherapeutic drug and an immunostimulating cytokine, wherein the chemotherapeutic drug is encapsulated in liposomes which contain about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 daltons.

15. The method of claim 14, wherein said administering produces a greater therapeutic effect than a combination of the effects produced by the liposome-encapsulated drug and the cytokine administered individually.

16. The method of claim 14, wherein the chemotherapeutic drug is selected from a chemotherapeutic anthraquinone, cis-platin, and a topoisomerase I inhibitor.

17. The method of claim 16, wherein the chemotherapeutic anthraquinone is adriamycin.

18. The method of claim 17, wherein the chemotherapeutic drug encapsulated in liposomes is DOXIL®.

19. The method of claim 14, wherein the topoisomerase I inhibitor is camptothecin or a camptothecin analog.

20. The method of claim 14, wherein the cytokine is selected from the group consisting of interleukin-2 (IL-2), IL-12, IL-15, IL-18, IFN-γ, IFN-α, IFN-β, TNF-α, G-CSF, and GM-CSF.

21. The method of claim 20, wherein the cytokine is IL-2.

22. The method of claim 14, wherein administration of the cytokine follows administration of
the liposome-encapsulated chemotherapeutic drug.

23. A composition for use in antitumor therapy, comprising a combination of components encapsulated in liposomes, wherein said components comprise a chemotherapeutic drug and an immunostimulating cytokine.

24. The composition of claim 23, wherein said combination is effective to produce, in a tumor-affected subject, a greater antitumor effect than a combination of the effects produced by the liposome-encapsulated components administered individually.

25. The composition of claim 23, wherein the chemotherapeutic drug is encapsulated in liposomes containing about 1-10 mole percent of a lipid having a polar head group derivatized with a polyethylene glycol (PEG) chain which has a molecular weight of between 750 and 10,000 daltons.

26. The composition of claim 23, wherein the chemotherapeutic drug is selected from a chemotherapeutic anthraquinone, cis-platin, and a topoisomerase I inhibitor.

27. The composition of claim 26, wherein the chemotherapeutic anthraquinone is adriamycin.

28. The composition of claim 27, wherein the chemotherapeutic drug encapsulated in liposomes is DOXIL®.

29. The composition of claim 23, wherein the cytokine is selected from the group consisting of interleukin-2 (IL-2), IL-12, IL-15, IL-18, IFN-γ, IFN-α, IFN-β, TNF-α, G-CSF, and GM-CSF.

30. The composition of claim 29, wherein the cytokine is IL-2.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

| IPC 6 | A61K9/127 | A61K38/19 |

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

| IPC 6 | A61K |

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>EP 0 546 951 A (THE LIPOSOME COMPANY, INC.) 16 June 1993</td>
<td>1, 2, 4, 6, 10, 13, 23, 26-29</td>
</tr>
<tr>
<td></td>
<td>see page 3, line 39 - page 4, line 5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 7, line 20 - line 28</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see claims 1-10</td>
<td></td>
</tr>
<tr>
<td>Y</td>
<td>DE 44 30 593 A (MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN) 22 February 1996</td>
<td>1, 2, 4, 6, 10, 13, 23, 26-29</td>
</tr>
<tr>
<td></td>
<td>see claim 19</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>WO 90 13293 A (SYRACUSE UNIVERSITY) 15 November 1990</td>
<td>1-30</td>
</tr>
<tr>
<td></td>
<td>see page 15, line 6 - page 16, line 9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 18, line 15 - line 27</td>
<td></td>
</tr>
<tr>
<td></td>
<td>see page 21, line 19 - line 38</td>
<td></td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

**Date of the actual completion of the international search**

10 May 1999

**Date of mailing of the international search report**

19/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-3040, Tx 31 657 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K
### INTERNATIONAL SEARCH REPORT

**PCT/IL 98/00586**

#### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
| A        | DATABASE WPI  
            Week 8814  
            Derwent Publications Ltd., London, GB;  
            AN 88-096332  
            XP002102116  
            & JP 63 048225 A (GREEN CROSS CORP)  
            , 29 February 1988  
            see abstract  
            ___ | 2,15 |
| A        | EP 0 433 765 A (CONSIGLIO NAZIONALE DELLE RICERCHE) 26 June 1991  
            see claims 1,2,4  
            ___ | 2,15 |
| A        | WO 85 00968 A (HEALTH RESEARCH, INC.)  
            14 March 1985  
            see claim 1  
            ___ | 1-22 |
| A        | WO 91 05545 A (LIPOSOME TECHNOLOGY, INC.)  
            2 May 1991  
            see claims 1,9  
            & US 5 013 556 A  
            cited in the application  
            ___ | 3-5,10,  
            11,20,  
            21,29,30 |
| A        | WO 91 05546 A (LIPOSOME TECHNOLOGY, INC.)  
            2 May 1991  
            see claims 7,8  
            & US 5 013 556 A  
            cited in the application  
            ___ | 3-7,9,  
            14,  
            16-18,  
            25-28 |
INTERNATIONAL SEARCH REPORT

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 1-22
   because they relate to subject matter not required to be searched by this Authority, namely:
   **Remark:** Although claims 1-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Nos.:
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. □ Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  

**Remark on Protest**

□ The additional search fees were accompanied by the applicant's protest.

□ No protest accompanied the payment of additional search fees.
# INTERNATIONAL SEARCH REPORT

Information on patent family members

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 546951 A</td>
<td>16-06-1993</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td>DE 4430593 A</td>
<td>22-02-1996</td>
<td>WO 9605821 A</td>
<td>29-02-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0776202 A</td>
<td>04-06-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3505744 T</td>
<td>12-12-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 4009338 A</td>
<td>14-01-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 4873088 A</td>
<td>10-10-1989</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 115401 T</td>
<td>15-12-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 122229 T</td>
<td>15-05-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 642679 B</td>
<td>28-10-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6637490 A</td>
<td>16-05-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 654120 B</td>
<td>27-10-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6898291 A</td>
<td>16-05-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2067133 A,C</td>
<td>21-04-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2067178 A,C</td>
<td>21-04-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69015207 D</td>
<td>26-01-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69015207 T</td>
<td>04-05-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69019366 D</td>
<td>14-06-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69019366 T</td>
<td>05-10-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 496835 T</td>
<td>17-07-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0496813 A</td>
<td>05-08-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0496835 A</td>
<td>05-08-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2071976 T</td>
<td>01-07-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 921763 A</td>
<td>21-04-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 921764 A</td>
<td>21-04-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3017060 T</td>
<td>30-11-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 14097 A</td>
<td>14-02-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 96069 A</td>
<td>08-12-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 96070 A</td>
<td>30-03-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10001431 A</td>
<td>06-01-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2667051 B</td>
<td>22-10-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5501264 T</td>
<td>11-03-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5505173 T</td>
<td>05-08-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 134982 B</td>
<td>22-04-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LU 88854 A</td>
<td>11-03-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5527528 A</td>
<td>18-06-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9105546 A</td>
<td>02-05-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5620689 A</td>
<td>15-04-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5225212 A</td>
<td>06-07-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5213804 A</td>
<td>25-05-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5843473 A</td>
<td>01-12-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5356633 A</td>
<td>18-10-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 115401 T</td>
<td>15-12-1994</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 122229 T</td>
<td>15-05-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 642679 B</td>
<td>28-10-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 6637490 A</td>
<td>16-05-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 654120 B</td>
<td>27-10-1994</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
<td>Publication date</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>----------------</td>
<td>-------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2067133 A</td>
<td>21-04-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2067178 A</td>
<td>21-04-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69015207 D</td>
<td>26-01-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69015207 T</td>
<td>04-05-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69019366 D</td>
<td>14-06-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69019366 T</td>
<td>05-10-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 496835 T</td>
<td>17-07-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0496813 A</td>
<td>05-08-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0496835 A</td>
<td>05-08-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2071976 T</td>
<td>01-07-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 921763 A</td>
<td>21-04-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 921764 A</td>
<td>21-04-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 3017060 T</td>
<td>30-11-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 14097 A</td>
<td>14-02-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 96069 A</td>
<td>08-12-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 96070 A</td>
<td>30-03-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10001431 A</td>
<td>06-01-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2667051 B</td>
<td>22-10-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5501264 T</td>
<td>11-03-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 5505173 T</td>
<td>05-08-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 134982 B</td>
<td>22-04-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LU 88854 A</td>
<td>11-03-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5527528 A</td>
<td>18-06-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9105545 A</td>
<td>02-05-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5620689 A</td>
<td>15-04-1997</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5225212 A</td>
<td>06-07-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5218304 A</td>
<td>25-05-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5843473 A</td>
<td>01-12-1998</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 5356633 A</td>
<td>18-10-1994</td>
</tr>
</tbody>
</table>